Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Xiang Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5942-7282; OpenAlex author ID A5100707026. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 21

  1. [18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Co-author DOI 10.1007/s00259-025-07271-6↗
  2. Siamese Delta Network with Multimodality Fusion for Systemic Treatment Response Prediction in Pancreatic Cancer. First author DOI 10.1109/embc40787.2023.10340012↗
  3. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  4. Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer. First author DOI 10.1002/jmri.27024↗
  5. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2020.01.001↗
  6. The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.11.012↗
  7. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.trsl.2020.02.004↗
  8. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.009↗
  9. Monitoring Tumor Burden in Response to FOLFIRINOX Chemotherapy Via Profiling Circulating Cell-Free DNA in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1298↗
  10. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Co-author DOI 10.1634/theoncologist.2018-0696↗
  11. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Co-author DOI 10.1038/s41388-017-0082-2↗
  12. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. Co-author DOI 10.1038/s41419-017-0158-5↗
  13. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Co-author DOI 10.1016/j.canlet.2017.07.012↗
  14. ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca2+/RhoA pathway. Co-author DOI 10.1038/cddis.2017.189↗
  15. MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Co-author DOI 10.1158/1535-7163.mct-15-0877↗
  16. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Co-author DOI 10.18632/oncotarget.6830↗
  17. Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. First author DOI 10.1038/gt.2015.39↗
  18. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Co-author DOI 10.1016/j.canlet.2014.08.007↗
  19. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Co-author DOI 10.1158/1535-7163.mct-12-0534-t↗
  20. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Co-author DOI 10.1158/1535-7163.mct-13-0296↗
  21. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. Co-author DOI 10.1371/journal.pone.0073803↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 7 shared papers, 2019–2023 · strength 0.73
  2. Xueli Bai · 6 shared papers, 2019–2023 · strength 0.66
  3. Risheng Que · 7 shared papers, 2017–2020 · strength 0.57
  4. Gang Zhao · 10 shared papers, 2013–2018 · strength 0.48
  5. Qi Zhang · 5 shared papers, 2019–2020 · strength 0.48
  6. Shichang Deng · 9 shared papers, 2013–2018 · strength 0.44
  7. Chunyou Wang · 9 shared papers, 2013–2018 · strength 0.44
  8. Xueli Bai · 3 shared papers, 2019–2025 · strength 0.42
  9. Tao Ma · 5 shared papers, 2017–2020 · strength 0.40
  10. Shuai Zhu · 7 shared papers, 2013–2018 · strength 0.35
  11. Tingbo Liang · 2 shared papers, 2020–2025 · strength 0.34
  12. Shi-Jiang Deng · 6 shared papers, 2014–2018 · strength 0.34
  13. Yan Jin · 5 shared papers, 2014–2018 · strength 0.29
  14. Qi Qin · 6 shared papers, 2013–2018 · strength 0.25
  15. Jianying Lou · 3 shared papers, 2019 · strength 0.24
  16. Qihan Fu · 2 shared papers, 2020 · strength 0.22
  17. Jingsong Li · 1 shared paper, 2023 · strength 0.22
  18. Peijun Hu · 1 shared paper, 2023 · strength 0.22
  19. Lili Lin · 1 shared paper, 2025 · strength 0.22
  20. Kang Sun · 1 shared paper, 2025 · strength 0.22
  21. Xinhui Su · 1 shared paper, 2025 · strength 0.22
  22. Lei Zheng · 3 shared papers, 2017–2019 · strength 0.22
  23. Yiwen Chen · 2 shared papers, 2019–2020 · strength 0.20
  24. Mingliang Liu · 3 shared papers, 2016–2018 · strength 0.19
  25. Wei Chen · 2 shared papers, 2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.